Random Analytica: AstraZeneca COVID-19 vaccine and cases of Thrombosis with thrombocytopenia syndrome (TTS) to 13 June 2021

The Therapeutic Goods Administration (TGA) has updated its latest safety report with no new deaths being reported. Via the TGA. COVID-19 vaccine weekly safety report – 17-06-2021. Summary:

  • The most frequently reported suspected side effects associated with Comirnaty (Pfizer) and AstraZeneca COVID-19 vaccines continue to be events that were seen in the clinical trials, and are commonly experienced with vaccines generally.
  • Twelve additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia syndrome (TTS) likely to be linked to the AstraZeneca vaccine. The increase in the number of cases correlates with an increase in the number of doses of AstraZeneca vaccine administered during the reporting period.
  • This brings the total number of confirmed and probable TTS cases in Australia to 60. Seven of the 12 new cases occurred in individuals in aged between 50 and 59 years. When assessed using the United Kingdom (UK) case definition, three cases were confirmed and nine were deemed probable TTS.

No data was available in this report on AstraZeneca vaccines administered (in the previous week 3.3-million doses were confirmed). At the same time the Australian Technical Advisory Group on Immunisation (ATAGI) recommended the age to receive a dose be increased from 50 to 60. To date there have been two TTS deaths linked to the AstraZeneca vaccine.